4 h. ago China’s biotech industry is gaining on the US. Can tariffs hold them back?

In the summer of 2015, a time when China’s pharmaceutical market was in a phase of rapid expansion, a sudden regulatory change sent tremors through the industry: drug companies would need to audit the clinical trial data for all pending applications. If withdrawn within a month of the announcement, firms could avoid penalties for submitting flawed applications, but hiding or falsifying data would court severe punishments, including multi-year filing bans. The response from the industry indicated...

Economics

18 h. ago China closes biotech gap with US as new drugs, pipelines top 30% of global total

China’s push to become a biotech powerhouse is paying off, with innovative R&D pipelines and newly approved drugs accounting for over 30 per cent of the global total, according to the country’s top economic planner. The sector was showing strong momentum, said Xiang Libin, deputy chairman of the National Development and Reform Commission (NDRC), who cited the figures at the 17th China Bioindustry Convention in Wuhan, Hubei province, on Thursday. China’s bioeconomy, encompassing the research,...

Events

21 h. ago China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

Jiangsu Hengrui Pharmaceuticals, a Chinese developer of novel drugs, could receive up to US$1.01 billion in milestone payments after granting a US company exclusive rights to develop a heart disease drug, the latest example of mainland drug makers licensing early-stage assets to international partners. Jiangsu Hengrui entered into a licensing agreement with one-year-old US start-up Braveheart Bio for its innovative drug HRS-1893 to treat obstructive hypertrophic cardiomyopathy, according to a...

Events

59 h. ago Novartis signs up to $5.2 billion licensing deal with China's biotech Argo for heart drugs

Novartis signs up to $5.2 billion licensing deal with China's biotech Argo for heart drugs  Reuters

Economics

8 d. ago XtalPi’s 615% jump in drug revenue highlights China’s biotech boom

Shenzhen-based XtalPi posted a 615 per cent surge in first-half revenue from its drug-discovery business following a blockbuster deal that highlighted China’s growing importance as a source of biotechnology innovation for the global pharmaceutical industry. Revenue from drug discovery soared to 435 million yuan (US$61 million) in the first half after the company collected the first US$51 million from an August agreement with US-based DoveTree, according to its earnings announcement on Wednesday....

Events

1 week ago Drugs from China are reshaping biotech. Track the licensing deals here.

Drugs from China are reshaping biotech. Track the licensing deals here.  BioPharma Dive

Events

2 w. ago China’s rise in biotech could lower healthcare costs, investor says

China’s rise in biotech innovation offers the world a potentially cheaper alternative to costly healthcare products from Western suppliers, but geopolitical tensions remain a major challenge for the country’s globalisation efforts, according to a local investor in the sector. “We can lower the cost of healthcare and benefit more people through technological innovation and efficiency improvement,” Da Liu, managing director of CR-CP Life Science Fund, said in an interview with the Post earlier...

Economics

2 w. ago China vows stronger biotech support as deals with global drug makers surge

Chinese Premier Li Qiang has called for stronger policy support for the biotech industry, as part of efforts to bolster innovation in a sector that has witnessed a boom in recent years. “The biopharmaceutical industry is both a strategic emerging sector and vital to public health,” he said during an inspection in Beijing on Wednesday, as reported by the state-run Xinhua News Agency. “Efforts should be made to strengthen original innovation, address core technological challenges and mobilise...

Events

2 w. ago China’s biotech hub Suzhou wants to become the next Boston. Can it succeed?

Could a city best known for its classical gardens and ancient canals emerge as China’s answer to Boston – the global epicentre of biotechnology innovation? Five years ago, the eastern city of Suzhou set forth a bold vision: to transform itself into the “Pharma Valley of China” by 2030, benchmarking its ambitions directly against Greater Boston’s world-leading life sciences ecosystem. The city in Jiangsu province, steeped in history and famous for its ancient water towns and picturesque gardens,...

Politics

2 w. ago The ancient Chinese city that dreams to become the world’s biotech powerhouse

Could a city best known for its classical gardens and ancient canals emerge as China’s answer to Boston – the global epicentre of biotechnology innovation? Five years ago, the eastern city of Suzhou set forth a bold vision: to transform itself into the “Pharma Valley of China” by 2030, benchmarking its ambitions directly against Greater Boston’s world-leading life sciences ecosystem. The city in Jiangsu province, steeped in history and famous for its ancient water towns and picturesque gardens,...

Politics

2 w. ago Opinion | China’s Biotech Is Cheaper and Faster Than America’s

Opinion | China’s Biotech Is Cheaper and Faster Than America’s  The New York Times

Politics